Table 2.
Targets of CAR-NK cell-based therapy for hematological malignancies
| Target | Tumor | NK cell sources | CAR structures | CAR transfer | Reference | Year |
|---|---|---|---|---|---|---|
| CD19 | B-ALL | PB | scFv-4-1BB-CD3ζ | Retrovirus | [77] | 2005 |
| CD19 | B-cell leukemia | PB | scFv-4-1BB-CD3ζ | mRNA electroporation | [78] | 2012 |
| CD19 | B-ALL | PB | scFv-CD28-CD3ζ | Lentivirus | [79] | 2016 |
| CD19 | B-cell precursor Leukemia | PB | scFv-CD28-4-1BB-CD3ζ | Retrovirus | [80] | 2016 |
| CD19 | B-cell lymphoma | NK-92 | scFv-CD28-4-1BB-CD3ζ | Lentivirus | [81] | 2017 |
| CD19 | B-cell malignancies | UCB | scFv-4-1BB-CD3ζ + iCasp9 + IL15 | Retrovirus | [82] | 2018 |
| CD19 | B-cell leukemia | NK-92 | scFv-4-1BB-CD3ζ | Lentivirus | [83] | 2020 |
| CD19 | B-cell lymphoma and precursor leukemia | PB | scFv-4-1BB-CD3ζ + CXCR4 | Lentivirus | [84] | 2020 |
| CD19 | B-ALL | PB | scFv-CD28-CD3ζ | Retrovirus | [53] | 2020 |
| CD19 | B-cell lymphoma | UCB | iC9 + scFv-CD28-CD3ζ + IL-15 | Retrovirus | [85] | 2021 |
| CD19/BCMA | B-cell malignancies | NK-92 | scFv-4-1BB-CD3ζ | mRNA electroporation | [86] | 2022 |
| CD20 | Burkitt lymphoma | PB | scFv-4-1BB-CD3ζ | mRNA electroporation | [87] | 2015 |
| CD20 | Burkitt lymphoma | PB | scFv-4-1BB-CD3ζ | mRNA electroporation | [88] | 2017 |
| CD138 | multiple myeloma | NK-92 | ScFv-CD3ζ | Lentivirus | [89] | 2014 |
| CS-1 | multiple myeloma | NK-92 | scFv-CD28-CD3ζ | Lentivirus | [90] | 2014 |
| BCMA | multiple myeloma | NK-92 | scFv-4-1BB-CD3ζ | Lentivirus | [91] | 2019 |
| BCMA | multiple myeloma | PB | ScFv-CD3ζ/DAP12 | mRNA electroporation | [92] | 2022 |
| CD38 | AML | PB | scFv-CD28-CD3ζ | mRNA electroporation | [93] | 2022 |
| CD38 | AML | PB | scFv-CD28-CD3ζ | mRNA electroporation | [68] | 2020 |
| CD33 | AML | PB | scFv-4-1BB-CD3ζ | Lentivirus | [94] | 2022 |
| CD5 | T-cell malignant cells | NK-92 | scFv-CD28-4-1BB-CD3ζ | Lentivirus | [95] | 2017 |
| CD5 | T-cell malignant cells | NK-92 | scFv-2B4-CD3ζ | Lentivirus | [96] | 2019 |
| CD7 | T-cell Leukemia | NK-92 | scFv-CD28-4-1BB-CD3ζ | mRNA electroporation | [97] | 2019 |
| CD123 | AML | PB | scFv-CD28-4-1BB-CD3ζ | Retrovirus | [98] | 2017 |
| CD123 | AML | NK-92 | scFv-CD28-4-1BB-CD3ζ | Retrovirus | [99] | 2021 |
| NKG2DL | AML | PB | NKG2D-CD28-4-1BB-CD3ζ | mRNA electroporation | [100] | 2021 |